P975: THREE-DIMENSIONAL TELOMERE PROFILING PREDICTS RISK OF RELAPSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
Bibliographic record
Abstract
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Multiple myeloma (MM) is a challenging and potentially deadly blood cancer that involves plasma cells. It is the second most common blood cancer with an incidence of approximately 35,000 new cases per year in the US, and 180,000 additional patients receiving treatment at any given time. Although the introduction of new generation therapy, including targeted immunotherapy, has increased the median survival rate to over 5 years, MM is still considered incurable due to the significant heterogeneity of the disease from patient to patient. MM treatment includes various combinations of drugs as most patients will develop resistance to treatment and relapse within a median of 2 years. Identifying newly diagnosed MM (NDMM) patients who will develop resistance to treatment prior to relapse will allow switching these patients to an alternative treatment regimen and potentially avoiding the relapse event. To date, identifying NDMM patients with high risk of developing drug resistance remains an important clinical need. Genomic instability has been shown to be a dynamic indicator of disease progression in genetic diseases, particularly cancer. Telomere dysfunction is an early event in genomic instability. The 3-dimensional spatial profiling of telomeres allowing for the quantification of telomere dysfunction using TeloView technology was shown to be effective in stratifying patients into their respective risk groups in several cancers, including multiple myeloma. In a recent study were NDMM patients were followed longitudinally for up to 5 years, TeloView analysis was able to identify several MM risk groups, suggesting a clinical utility for TeloView analysis to predict the risk to develop drug resistance and relapse for MM patients up to ~13 months prior to the relapse event. Aims: In this study we analyzed a cohort of 178 NDMM patients. All patients received initial treatment using a regimen containing bortezomib or lenalidomide. The patient cohort included 2 patient groups, one group relapsed within 12 months and the other group remained in remission for over 3 years. Methods: Using TeloView technology we quantified 6 molecular and spatial telomeric parameters. We then conducted univariate and bivariate analyses using nested methodologies to identify telomere parameters that are significantly different between the 2 patient groups, suitable to be used as predictors in regression analysis. We then employed these significant parameters as predictors in multivariate analysis. Results: Four out of the measured telomere parameters were found significant with p-values <0.04 and equality of variance <0.01. The significant parameters included telomere length, number of detectable telomeres, % of telomere stumps and the a/c ratio (a measure of cell cycle progression). We generated ROC curves to develop a predictive scoring model able to predict risk of relapse on the level of the individual patient. The ROC curve analysis revealed AUC of 0.82 (82% accuracy) and corresponding specificity of 0.85 (85%) and sensitivity of 0.72 (72%). We examined the confidence of the generated predictive model using the Likelihood ratio, Wald and Scoring tests. The model showed confidence with p-values of <0.001 in all 3 tests. Summary/Conclusion: The result of this study presents TeloView as an accurate prognostic biomarker which appears able to predict the risk of NDMM patients to develop resistance to first-line therapy combinations that include bortezomib and/ or lenalidomide. Further validation of the developed scoring model using an independent patient cohort is underway. Keywords: Multiple myeloma, Telomere, Drug resistance, Relapse
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".